Tracking John Paulson's Paulson & Company Portfolio - Q4 2025 Update

John Vincent26.09K FollowersFollow5ShareSavePlay(13min)Comment(1)SummaryJohn Paulson's Q4 2025 13F portfolio rose to ~$3.26B, concentrated in nine securities, with Madrigal Pharma as the largest holding.MDGL, now 31% of the portfolio, saw an ~11% reduction this quarter; Paulson retains a 6.7% ownership stake.Significant activity included a new Solstice Advanced Materials position, minor increases in Bausch Health and Thryv, and disposal of Honeywell and Trilogy Metals.Paulson maintains high-conviction stakes in Perpetua Resources, Acadian Asset Management, and NovaGold, reflecting a focused, high-ownership investment approach.TimArbaev/iStock via Getty Images This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F filed on 02/17/2026. PleaseThis article was written byJohn Vincent26.09K FollowersFollowFocused on analyzing 13F reports & building tools to help DIY investors generate absolute returns through exploiting inefficiency, volatility, and momentum.

Asymmetric Bets Focus. Broader commentary for DIY investors at Substack: https://diyabsolutereturns.substack.com/ . Check out my books in the Demystifying Web3 and Beyond series: 1. Demystifying Bitcoin: Paving the Way to Global Digital Money.2. Demystifying Crypto: Powering a Borderless Digital Economy.Analyst’s Disclosure: I/we have a beneficial long position in the shares of PPTA, NG, FNMA, FMCC, IBIT, ETHA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.